Bausch + Lomb advances dry-eye Phase 3 candidate, BL1332 Phase 1b
Bausch + Lomb moves its dual-action dry-eye candidate into Phase 3 after mixed Phase 2 results and reports positive Phase 1b ocular-surface pain data for BL1332.
BLCO is advancing two potential first-in-class eye therapies: a dual-action dry-eye treatment entering Phase 3 and BL1332, which produced positive Phase 1b data for ocular-surface pain.
The Details: • Dry-eye program: A Phase 2 trial showed a significant benefit versus lifitegrast on Day 15, but did not meet its Day 29 primary endpoint. • BL1332 progress: The therapy met its Phase 1b primary endpoint by significantly reducing ocular-surface pain compared with vehicle; Phase 2 results are expected in coming months. • Development stage: Bausch + Lomb ($BLCO) now moves the dry-eye candidate into Phase 3, while BL1332 advances through Phase 2 evaluation. • Commercial potential: Bausch + Lomb ($BLCO) estimates combined peak sales above $2 billion—about $700 million for the dry-eye therapy and $1.4 billion for BL1332—if development and commercialization succeed.